Bemiparin is a low molecular weight heparin (LMWH) indicated for the acute treatment of deep vein thrombosis with or without pulmonary embolism, for the prophylaxis of venous thromboembolism in surgical and non-surgical patients and for the prevention of clotting in the extracorporeal circuit during hemodialysis. Due to its excellent pharmacological profile-the second-generation LMWH with the lowest molecular weight, the longest half-life and the highest anti-Factor Xa/anti-Factor IIa activity ratio-it can be safely used in special categories of patients (children, elderly, patients with renal impairment and congestive heart failure). Several studies demonstrated its safety and efficacy, while cost analyses show the economic benefits of bemiparin treatment as compared to other heparins. Recent evidences suggested the application of bemiparin even in the management of diabetic foot ulcers. The aim of this narrative review was to evaluate literature according to results coming from studies involving bemiparin administration in various clinical conditions.
Keywords: Acenocoumarol (PubChem CID: 54676537); Bemiparin; Bemiparin (PubChem CID: 25244225); Dabigatran (PubChem CID: 216210); Enoxaparin (PubChem CID: 772); Fondaparinux (PubChem CID: 5282448); Heparin (PubChem CID: 444410); Idraparinux (PubChem CID: 3083445); Low molecular weight heparin; Prevention; Rivaroxaban (PubChem CID: 9875401); Venous thromboembolism; Warfarin (PubChem CID: 54678486).
Copyright © 2014 Elsevier Inc. All rights reserved.